Mustang Bio IncMBIO
Price$0.47

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$3MTTM through 30 Jun 2026
Free Cash Flow -$4.5MTTM through 30 Jun 2026

Margins

Current
Gross Margin0.0%

Returns

-40.2%ROE
-19.4%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio2.22x
Net Debt-$16.3Mnet cash position
Cash & Equivalents$15.2M

Quality Metrics

Altman Z-Score-35.63
Piotroski F-Score1 / 9
Earnings-Beat Rate50.0%

Multi-Year Trend

Diluted EPS-$0.42TTM
'21'22'23'24'25
FY2025: $-0.39

Dividend

No dividend

Segment Performance

SegmentRevenueYoYOutlook
Research and Development$0
View details

Pipeline development is focused on clinical trials for MB-106 and investigator-sponsored trials for MB-109.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.